Belite Bio, Inc American Depositary Shares (BLTE)
Company News
Belite Bio secured a $125 million private placement financing led by RA Capital Management, with potential for an additional $150 million through warrant exercises, to support its clinical-stage drug development for retinal degenerative diseases.
The consensus price target hints at a 41.1% upside potential for Belite Bio (BLTE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Over the past 3 months, 4 analysts have published their opinion on Belite Bio (NASDAQ:BLTE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 0 0 0 0 3M Ago 0 0 0 0 Full story available on Benzinga.com
The clinical-stage biotech company bounced back from a 52-week low late last week.